Aduhelm’s Medicare woes leave questions about lofty premiums

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. The approval of Biogen’s Aduhelm continues to have ripple effects across healthcare. Most recently, it’s rattled the payer landscape for Medicare, potentially triggering longer-term changes to how the government approaches payments for high-cost drugs. Last Friday, the … Read more